Pacer Advisors Inc. grew its position in Amdocs Limited (NASDAQ:DOX – Free Report) by 7.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,815,675 shares of the technology company’s stock after buying an additional 125,654 shares during the quarter. Pacer Advisors Inc.’s holdings in Amdocs were worth $154,587,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in DOX. Private Trust Co. NA raised its position in Amdocs by 62.9% during the third quarter. Private Trust Co. NA now owns 303 shares of the technology company’s stock valued at $27,000 after buying an additional 117 shares during the period. Brooklyn Investment Group purchased a new position in Amdocs during the 3rd quarter valued at about $28,000. Catalyst Capital Advisors LLC acquired a new position in shares of Amdocs in the 3rd quarter valued at about $55,000. GAMMA Investing LLC lifted its position in shares of Amdocs by 115.1% in the third quarter. GAMMA Investing LLC now owns 800 shares of the technology company’s stock worth $70,000 after purchasing an additional 428 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new stake in shares of Amdocs during the third quarter worth approximately $77,000. 92.02% of the stock is currently owned by institutional investors and hedge funds.
Amdocs Stock Up 0.8 %
DOX stock opened at $85.28 on Monday. The firm has a market cap of $9.63 billion, a PE ratio of 20.11, a PEG ratio of 1.42 and a beta of 0.71. Amdocs Limited has a 1 year low of $74.41 and a 1 year high of $94.04. The company has a fifty day simple moving average of $85.69 and a 200 day simple moving average of $86.15. The company has a current ratio of 1.20, a quick ratio of 1.20 and a debt-to-equity ratio of 0.21.
Amdocs Dividend Announcement
Wall Street Analysts Forecast Growth
Several research firms have weighed in on DOX. Oppenheimer upped their price objective on shares of Amdocs from $98.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. StockNews.com lowered Amdocs from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 14th. Stifel Nicolaus began coverage on Amdocs in a research report on Wednesday, October 2nd. They set a “buy” rating and a $100.00 price objective for the company. Finally, Barclays dropped their target price on Amdocs from $113.00 to $111.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $101.20.
Amdocs Profile
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
Featured Articles
- Five stocks we like better than Amdocs
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Why These 3 Stocks With High Call Option Volume Deserve Attention
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- D-Wave: Recent Updates Propel Shares Off 2025 Lows
- What Does Downgrade Mean in Investing?
- Health-Tech Revival: 3 Stocks Set for a Big 2025 Rebound
Want to see what other hedge funds are holding DOX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amdocs Limited (NASDAQ:DOX – Free Report).
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.